Drug interactions between Cotellic and Zelboraf
Interactions between your drugs
- Cotellic is in the drug class multikinase inhibitors.
- Cotellic is used to treat Melanoma, Metastatic.
- Zelboraf is a member of the drug class multikinase inhibitors.
- Zelboraf is used to treat the following conditions:
Drug and food interactions
Applies to: Cotellic (cobimetinib)
Grapefruit juice may increase the blood levels and effects of certain medications such as cobimetinib. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with cobimetinib. However, if you have been regularly consuming grapefruit or grapefruit juice with cobimetinib, do not alter the amounts of these products in your diet without first talking to your doctor or other healthcare professional. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- cobimetinib (active ingredient in Cotellic (cobimetinib))
- vemurafenib (active ingredient in Zelboraf (vemurafenib))
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.